Practical aspects of deciding whether HIFU is an appropriate treatment “for you”

An article by Julie Appleby of Kaiser Health News, posted yesterday on the STAT health news web site, asks whether high-intensity focused ultrasound (HIFU) is being “over-sold” to prostate cancer patients based on the limited outcome data currently available. … READ MORE …

Salvage HIFU in men with a rising PSA after first-line surgery

We have long presumed that it would be possible to consider high-intensity focused ultrasound (HIFU) as a form of salvage therapy for men with biochemically recurrent disease after either surgery or radiation therapy. Now there are some data on this concept. … READ MORE …

Let’s call this “new technology” what it is; it’s a form of HIFU

According to information in the Boston Herald earlier today, researchers at Brigham & Women’s Hospital in Boston (one of the main teaching hospitals associated with Harvard University) are testing a new form of technology to treat localized prostate cancer. … READ MORE …

5-year outcomes from a large cohort of HIFU-treated patients in the UK

For several years now, the Ahmed/Emberton-led research team in the United Kingdom (UK) has published the majority of the detailed outcomes data from treatment of men with localized prostate cancer using high-intensity focused ultrasound (HIFU). This group has now given us 5-year outcomes on a cohort of > 550 patients. … READ MORE …

Data from a prospective trial of HIFU-based hemiablation for localized prostate cancer

A new report provides data from a prospective, single-center, Phase II trial of high-intensity focused ultrasound (HIFU) in prostate cancer hemiablation as a form of focal therapy. The study was carried out in Belgium. … READ MORE …

FDA approves EDAP TMS’s Ablatherm technology for HIFU therapy

As predicted, the U.S. Food and Drug Administration apparently approved the Ablatherm brand of equipment for high-intensity focused ultrasound (HIFU) on November 9 for “the ablation of prostate tissue.” … READ MORE …

Focal HIFU is “sexual function sparing” in a cohort of 118 selected patients

A new paper in European Urology has suggested that men with localized prostate cancer who are treated by focal forms of high-intensity focused ultrasound (HIFU) have “a return to baseline International Index of Erectile Function — erectile and total International Index of Erectile Function scores” by 6 months after treatment which was maintained at 1 year. … READ MORE …